Core Insights - Sonic Automotive, Inc. is under investigation for possible violations of federal securities laws, as announced by Levi & Korsinsky [1] - The company reported a 33% decline in net income for Q3 2025, attributed to increased medical expenses and a higher effective income tax rate [2] - Following the financial results announcement, Sonic Automotive's stock price dropped over 15% on the same day [2] Company Financial Performance - Sonic Automotive's net income decreased by 33% in Q3 2025 [2] - The decline in net income was primarily due to significant increases in medical expenses and a higher effective income tax rate [2] Stock Market Reaction - The stock price of Sonic Automotive fell by more than 15% on October 23, 2025, immediately after the financial results were released [2]

Core Viewpoint - Replimune Group, Inc. is under investigation for potential violations of federal securities laws following a significant decline in its stock price after receiving a Complete Response Letter from the FDA regarding its lead product RP1 [1][3]. Company Summary - Replimune received a Complete Response Letter from the FDA on July 22, 2025, indicating that its IGNYTE trial was not considered adequate for demonstrating the effectiveness of RP1 in combination with nivolumab for advanced melanoma [3]. - Following the FDA's announcement, Replimune's stock price fell by $9.52, or approximately 77.24%, closing at $2.81 per share [3]. Legal Investigation Summary - Kirby McInerney LLP is investigating potential claims against Replimune and its officers for possible violations of federal securities laws and other unlawful business practices [1][4].